Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan

被引:0
|
作者
Shibata, Yasushi [1 ]
Sato, Hiroshige [2 ]
Sato, Akiko [3 ]
Harada, Yoichi [4 ]
机构
[1] Univ Tsukuba, Mito Med Ctr, Dept Neurosurg, Mito 3100015, Japan
[2] Sato Clin Internal Med & Neurosurg, Dept Neurosurg, Moriya, 6750115, Japan
[3] Sato Clin Internal Med & Neurosurg, Dept Neurol, Moriya 3020117, Japan
[4] Mito Brain Heart Ctr, Dept Neurosurg, Mito 3100004, Japan
来源
NEUROLOGY INTERNATIONAL | 2024年 / 16卷 / 03期
关键词
migraine; triptan; lasmiditan; step care; CGRP;
D O I
10.3390/neurolint16030048
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The combined use of lasmiditan and triptan is unexplored in medical literature. This study aimed to investigate whether the intake of lasmiditan following triptan improves migraine pain. Following triptan intake, if headache relief was less than 50% at 1 h, patients took 50 mg of lasmiditan within 2 h of migraine onset. Patients recorded headache intensity and adverse events (AEs) caused by lasmiditan at 1, 2, and 4 h after the intake of an additional 50 mg of lasmiditan. A significant reduction in pain scale was observed post 50 mg lasmiditan intake (p < 0.001, t-test). Pain relief was reported for 32 migraine attacks (80%) at 1 h after additional lasmiditan intake. Although AEs were observed in 63% of the patients who took an additional lasmiditan, most were mild and resolved 1 h after lasmiditan intake. Our study revealed the significant headache relief provided by an additional lasmiditan for patients who did not achieve satisfactory results following initial triptan intake for treating migraine. The AEs associated with this treatment strategy were mild and lasted for a short time. This study suggested that the combination of triptan and lasmiditan is promising for the treatment of migraine and should be studied in a randomized placebo-controlled trial.
引用
收藏
页码:643 / 652
页数:10
相关论文
共 50 条
  • [1] Lasmiditan in the treatment of migraine attacks
    Kopka, Marcin
    AKTUALNOSCI NEUROLOGICZNE, 2019, 19 (04): : 179 - 182
  • [2] Timing of triptan treatment in migraine attacks and treatment satisfaction
    Lohman, Joseph
    Van der Kuy-de Ree, M. M.
    CEPHALALGIA, 2007, 27 (06) : 732 - 732
  • [3] Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy
    Knievel, Kerry
    Lombard, Louise
    Buchanan, Andrew
    Baygani, Simin
    Raskin, Joel
    Tobin, Joshua
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [4] Efficacy of Lasmiditan for the Acute Treatment of Perimenstrual Migraine
    MacGregor, A.
    Komori, M.
    Krege, J.
    Dong, Y.
    Vincent, M.
    Hauck, P.
    Igarashi, H.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 146 - 146
  • [5] Efficacy of Lasmiditan for the Acute Treatment of Perimenstrual Migraine
    MacGregor, A.
    Komori, M.
    Krege, J.
    Dong, Y.
    Vincent, M.
    Hauck, P.
    Igarashi, H.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 98 - 98
  • [6] Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy
    Buchanan, A. S.
    Knievel, K.
    Lombard, L.
    Baygani, S.
    Raskin, J.
    Tobin, J. A.
    HEADACHE, 2019, 59 : 103 - 103
  • [7] Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
    MacGregor, E. Anne
    Komori, Mika
    Krege, John Henry
    Baygani, Simin
    Vincent, Maurice
    Pavlovic, Jelena
    Igarashi, Hisaka
    CEPHALALGIA, 2022, 42 (14) : 1467 - 1475
  • [8] Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
    MacGregor, E.
    Komori, M.
    Krege, J. H.
    Dong, Y.
    Vincent, M.
    Igarashi, H.
    Hauck, P.
    HEADACHE, 2021, 61 : 125 - 125
  • [9] Lasmiditan for the treatment of migraine
    Capi, Matilde
    de Andres, Fernando
    Lionetto, Luana
    Gentile, Giovanna
    Cipolla, Fabiola
    Negro, Andrea
    Borro, Marina
    Martelletti, Paolo
    Curto, Martina
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (02) : 227 - 234
  • [10] Onset of Efficacy Following Oral Treatment with Lasmiditan for the Acute Treatment of Migraine
    Ashina, M.
    Vasudeva, R.
    Jin, L.
    Lombard, L.
    Gray, E.
    Doty, E. G.
    Yunes-Medina, L.
    Tassorelli, C.
    HEADACHE, 2019, 59 : 93 - 93